Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.43B | $2.57B | $3.00B | $2.91B | $2.92B | $3.27B | $3.49B | $3.92B |
| Cost of revenue | $736.0M | $836.0M | $994.0M | $1.27B | $1.28B | $1.38B | $1.46B | $1.52B |
| Gross profit | $1.70B | $1.73B | $2.01B | $1.64B | $1.63B | $1.89B | $2.03B | $2.40B |
| Gross margin | 69.7% | 67.5% | 66.9% | 56.4% | 56.0% | 57.8% | 58.1% | 61.2% |
| R&D | $394.0M | $407.0M | $385.0M | $426.0M | $392.0M | $466.0M | $515.0M | $631.0M |
| Operating income | $264.0M | $292.0M | $479.0M | −$80.0M | −$96.0M | −$14.0M | $150.0M | $302.0M |
| EBITDA | $451.0M | $573.0M | $664.0M | $227.0M | $154.0M | $258.0M | $380.0M | $544.0M |
| Net income | $181.0M | $344.0M | $270.0M | −$158.0M | −$170.0M | −$50.0M | $25.0M | $219.0M |
| Net margin | 7.4% | 13.4% | 9.0% | -5.4% | -5.8% | -1.5% | 0.7% | 5.6% |
| EPS (diluted) | 0.92 | 1.75 | 1.36 | -0.79 | -0.78 | -0.23 | 0.11 | 0.99 |
Annual figures · source: Financial Modeling Prep
No one on the platform currently holds AKABY.
No tracked institution reports a position in AKABY as of their last filing.
No one on the platform has traded AKABY yet.
| $705M |
| — |
| GBTGlobal Blood Therapeutics, Inc. | $68.49 | +0.01% | $0 | — |
| ISEEIVERIC bio, Inc. | $39.95 | +0.38% | $5.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.